{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T13:24:41Z","timestamp":1783085081089,"version":"3.54.6"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T00:00:00Z","timestamp":1675987200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T00:00:00Z","timestamp":1675987200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Caen University Hospital"},{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1007\/s40120-023-00440-5","type":"journal-article","created":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T21:37:37Z","timestamp":1676065057000},"page":"529-542","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Real-World Effectiveness of Natalizumab Extended Interval Dosing in a French Cohort"],"prefix":"10.1007","volume":"12","clinical-trial-number":[{"clinical-trial-number":"nct04580381","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Juliette","family":"Pelle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anais R.","family":"Briant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Branger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Derache","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Arnaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Lebrun-Frenay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikael","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lydiane","family":"Mondot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerome","family":"De Seze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Bigaut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Collongues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Kremer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damien","family":"Ricard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavie","family":"Bompaire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Ohlmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magali","family":"Sallansonnet-Froment","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Ciron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damien","family":"Biotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice","family":"Pignolet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Jacques","family":"Parienti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1343-5858","authenticated-orcid":false,"given":"Gilles","family":"Defer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,10]]},"reference":[{"key":"440_CR1","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/S1474-4422(09)70021-3","volume":"8","author":"E Havrdova","year":"2009","unstructured":"Havrdova E, Galetta S, Hutchinson M, et al. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing\u2013Remitting Multiple Sclerosis (AFFIRM) study. Lancet Neurol. 2009;8:254\u201360.","journal-title":"Lancet Neurol"},{"key":"440_CR2","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1056\/NEJMoa020696","volume":"348","author":"DH Miller","year":"2003","unstructured":"Miller DH, Khan OA, Sheremata WA, et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2003;348:15\u201323.","journal-title":"N Engl J Med"},{"key":"440_CR3","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1056\/NEJMoa044397","volume":"354","author":"CH Polman","year":"2006","unstructured":"Polman CH, O\u2019Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354:899\u2013910.","journal-title":"N Engl J Med"},{"key":"440_CR4","doi-asserted-by":"crossref","unstructured":"Butzkueven H, Kappos L, Wiendl H, et al. Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP). J Neurol Neurosurg Psychiatry. 2020;91:660\u20138.","DOI":"10.1136\/jnnp-2019-322326"},{"key":"440_CR5","doi-asserted-by":"crossref","unstructured":"Horakova D, Uher T, Krasensky J, et al. Long-term effectiveness of natalizumab on MRI outcomes and no evidence of disease activity in relapsing-remitting multiple sclerosis patients treated in a Czech Republic real-world setting: a longitudinal, retrospective study. Mult Scler Relat Disord. 2020;46:102543.","DOI":"10.1016\/j.msard.2020.102543"},{"key":"440_CR6","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/s12883-019-1337-z","volume":"19","author":"J Perumal","year":"2019","unstructured":"Perumal J, Fox RJ, Balabanov R, et al. Outcomes of natalizumab treatment within 3 years of relapsing-remitting multiple sclerosis diagnosis: a prespecified 2-year interim analysis of STRIVE. BMC Neurol. 2019;19:116\u201327.","journal-title":"BMC Neurol"},{"key":"440_CR7","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1056\/NEJMoa1107829","volume":"366","author":"G Bloomgren","year":"2012","unstructured":"Bloomgren G, Richman S, Hotermans C, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med. 2012;366:1870\u201380.","journal-title":"N Engl J Med"},{"key":"440_CR8","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/S1474-4422(17)30282-X","volume":"16","author":"P-R Ho","year":"2017","unstructured":"Ho P-R, Koendgen H, Campbell N, Haddock B, Richman S, Chang I. Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies. Lancet Neurol. 2017;16:925\u201333.","journal-title":"Lancet Neurol"},{"key":"440_CR9","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1136\/jnnp-2016-315106.113","volume":"87","author":"C McGuigan","year":"2016","unstructured":"McGuigan C, Craner M, Guadagno J, et al. Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group. J Neurol Neurosurg Psychiatry. 2016;87:117\u201325.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"440_CR10","unstructured":"Biogen. Tysabri\u00ae (natalizumab): prescribing information. Cambridge: Biogen, Inc; 2021."},{"key":"440_CR11","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1212\/WNL.52.5.1072","volume":"52","author":"WA Sheremata","year":"1999","unstructured":"Sheremata WA, Vollmer TL, Stone LA, Willmer-Hulme AJ, Koller M. A safety and pharmacokinetic study of intravenous natalizumab in patients with MS. Neurology. 1999;52:1072.","journal-title":"Neurology"},{"key":"440_CR12","doi-asserted-by":"publisher","first-page":"P06.166","DOI":"10.1212\/WNL.78.1_MeetingAbstracts.P06.166","volume":"78","author":"G Defer","year":"2012","unstructured":"Defer G, Mariotte D, Derache N, et al. Increase of infusion interval do not impair natalizumab efficacy in RR-MS patients: a pilot study based on monthly monitoring of CD49d. Neurology. 2012;78:P06.166.","journal-title":"Neurology"},{"key":"440_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.549842","volume":"11","author":"K Khoy","year":"2020","unstructured":"Khoy K, Mariotte D, Defer G, Petit G, Toutirais O, Le Mauff B. Natalizumab in multiple sclerosis treatment: from biological effects to immune monitoring. Front Immunol. 2020;11:549842.","journal-title":"Front Immunol"},{"key":"440_CR14","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.jns.2011.10.005","volume":"314","author":"G Defer","year":"2012","unstructured":"Defer G, Mariotte D, Derache N, et al. CD49d expression as a promising biomarker to monitor natalizumab efficacy. J Neurol Sci. 2012;314:138\u201342.","journal-title":"J Neurol Sci"},{"key":"440_CR15","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1177\/1352458517708464","volume":"24","author":"ZL van Kempen","year":"2018","unstructured":"van Kempen ZL, Leurs CE, Witte BI, et al. The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing. Mult Scler. 2018;24:805\u201310.","journal-title":"Mult Scler"},{"key":"440_CR16","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000672","volume":"7","author":"L Zhovtis Ryerson","year":"2020","unstructured":"Zhovtis Ryerson L, Li X, Goldberg JD, et al. Pharmacodynamics of natalizumab extended interval dosing in MS. Neurol Neuroimmunol Neuroinflamm. 2020;7:e672.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"440_CR17","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1002\/ana.22074","volume":"68","author":"J Killestein","year":"2010","unstructured":"Killestein J, Vennegoor A, Strijbis EM, et al. Natalizumab drug holiday in multiple sclerosis: poorly tolerated. Ann Neurol. 2010;68:392\u20135.","journal-title":"Ann Neurol"},{"key":"440_CR18","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1177\/1352458510392098","volume":"17","author":"G Borriello","year":"2011","unstructured":"Borriello G, Prosperini L, Marinelli F, Fubelli F, Pozzilli C. Observations during an elective interruption of natalizumab treatment: a post-marketing study. Mult Scler. 2011;17:372\u20135.","journal-title":"Mult Scler"},{"key":"440_CR19","first-page":"e1452","volume":"93","author":"L Zhovtis Ryerson","year":"2019","unstructured":"Zhovtis Ryerson L, Foley J, Chang I, et al. Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing. Neurology. 2019;93:e1452\u201362.","journal-title":"Neurology"},{"key":"440_CR20","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1177\/1756285614540224","volume":"7","author":"R Bomprezzi","year":"2014","unstructured":"Bomprezzi R, Pawate S. Extended interval dosing of natalizumab: a two-center, 7-year experience. Ther Adv Neurol Disord. 2014;7:227\u201331.","journal-title":"Ther Adv Neurol Disord"},{"key":"440_CR21","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1136\/jnnp-2020-323472","volume":"91","author":"CG Chisari","year":"2020","unstructured":"Chisari CG, Grimaldi LM, Salemi G, et al. Clinical effectiveness of different natalizumab interval dosing schedules in a large Italian population of patients with multiple sclerosis. J Neurol Neurosurg Psychiatry. 2020;91:1297\u2013303.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"440_CR22","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1007\/s13311-019-00776-7","volume":"17","author":"M Clerico","year":"2020","unstructured":"Clerico M, De Mercanti SF, Signori A, et al. Extending the interval of natalizumab dosing: is efficacy preserved? Neurotherapeutics. 2020;17:200\u20137.","journal-title":"Neurotherapeutics"},{"key":"440_CR23","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1007\/s00415-014-7558-6","volume":"262","author":"M Kaufman","year":"2015","unstructured":"Kaufman M, Cree BAC, De S\u00e8ze J, et al. Radiologic MS disease activity during natalizumab treatment interruption: findings from RESTORE. J Neurol. 2015;262:326\u201336.","journal-title":"J Neurol"},{"key":"440_CR24","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1136\/jnnp-2015-312940","volume":"87","author":"L Zhovtis Ryerson","year":"2016","unstructured":"Zhovtis Ryerson L, Frohman TC, Foley J, et al. Extended interval dosing of natalizumab in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2016;87:885\u20139.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"440_CR25","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1177\/13524585211003020","volume":"27","author":"M Trojano","year":"2021","unstructured":"Trojano M, Rami\u00f3-Torrent\u00e0 L, Grimaldi LME, et al. A randomized study of natalizumab dosing regimens for relapsing\u2013remitting multiple sclerosis. Mult Scler. 2021;27:2240\u201353.","journal-title":"Mult Scler"},{"key":"440_CR26","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1002\/jcph.1737","volume":"61","author":"I Chang","year":"2021","unstructured":"Chang I, Muralidharan KK, Campbell N, Ho PR. Modeling the efficacy of natalizumab in multiple sclerosis patients who switch from every-4-week dosing to extended-interval dosing. J Clin Pharmacol. 2021;61:339\u201348.","journal-title":"J Clin Pharmacol"},{"key":"440_CR27","doi-asserted-by":"crossref","unstructured":"Foley J, Defer G, Zhovtis Ryerson L, et al. Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial. Lancet Neurol. 2022;21:608\u201319.","DOI":"10.1016\/S1474-4422(22)00143-0"},{"key":"440_CR28","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1002\/ana.24339","volume":"77","author":"T Kalincik","year":"2015","unstructured":"Kalincik T, Horakova D, Spelman T, et al. Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis. Ann Neurol. 2015;77:425\u201335.","journal-title":"Ann Neurol"},{"key":"440_CR29","doi-asserted-by":"publisher","first-page":"13650","DOI":"10.1038\/s41598-018-31911-7","volume":"8","author":"O Commowick","year":"2018","unstructured":"Commowick O, Istace A, Kain M, et al. Objective evaluation of multiple sclerosis lesion segmentation using a data management and processing infrastructure. Sci Rep. 2018;8:13650.","journal-title":"Sci Rep"},{"key":"440_CR30","doi-asserted-by":"publisher","first-page":"e745","DOI":"10.1212\/WNL.0000000000009995","volume":"95","author":"ZLE van Kempen","year":"2020","unstructured":"van Kempen ZLE, Hoogervorst ELJ, Wattjes MP, et al. Personalized extended interval dosing of natalizumab in MS: a prospective multicenter trial. Neurology. 2020;95:e745\u201354.","journal-title":"Neurology"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-023-00440-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-023-00440-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-023-00440-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,27]],"date-time":"2023-03-27T11:31:24Z","timestamp":1679916684000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-023-00440-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,10]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["440"],"URL":"https:\/\/doi.org\/10.1007\/s40120-023-00440-5","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,10]]},"assertion":[{"value":"9 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}